Study of Atezolizumab Combination Carboplatin + Paclitaxel + Bevacizumab in EGRF Mutation or ALK Translocation NSCLC
Status:
Recruiting
Trial end date:
2022-12-31
Target enrollment:
Participant gender:
Summary
This randomized, Phase III, multicenter, open-label study designed to evaluate the efficacy
of Atezolizumab in combination with carboplatin, paclitaxel, bevacizumab compared with
treatment with pemetrexed, cisplatin in approximately 228 TKI(tyrosine kinase inhibitor) pre
treated patients with Stage IV non squamous non small cell lung cancer with activating EGFR
mutation or ALK translocation.